智通财经APP讯，百奥赛图-B(02315)发布截至2024年12月31日止年度业绩快报，预计集团2024年营业收入约为9.74亿元(人民币，下同)至9.84亿元，与上年同期的财务报表数据相比，将增加约2.57亿元至2.67亿元，同比增加约35.8%至37.2%。预计集团2024年年度净利润约为2730万元至3730万元，同比扭亏为盈。
据悉，上年同期营业收入约为7.17亿元;年度亏损约为3.83亿元。
公告称，业绩保持良好增长主要归因于以下因素：抗体发现业务获得更多海外客户的认可，对外转让的抗体分子数量快速增加，销售收入快速增长的同时，毛利率维持较高水平;基因编辑动物模型业务继续保持快速增长，尤其是海外市场持续开拓，使得海外业务收入贡献比例进一步提高，同时保持了较高的毛利率水平;及集团战略调整成效显著，研发投入同比下降明显，精益管理初见成效。集团聚焦研发方向，研发活动集中服务于主要业务条线的中长期发展。集团努力提升运营效率，管控成本开支。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.